Fabtech Technologies Limited, a global provider of integrated design, engineering and build solutions for regulated manufacturing environments, has secured a INR 21 crore turnkey project in a CIS country. The order marks Fabtech’s entry into this CIS market and expands the Company’s international execution footprint into a technically demanding geography.

Project Scope

The project involves the development of critical internal infrastructure for an advanced medical-device manufacturing facility. Fabtech’s scope includes integrated engineering and design, cleanroom systems, HVAC, building management systems, electrical systems, process and clean utilities, laboratory and cleanroom furniture, fire and life-safety systems, installation, testing and commissioning.

Strategic Impact

Strategically, the order opens a new geography for Fabtech while demonstrating the portability of its integrated Design-Engineer-Build model across markets with materially different climatic, regulatory and infrastructure conditions. The entry into this CIS country further strengthens Fabtech’s growing international business and its positioning as a single-point partner for complex, regulated manufacturing infrastructure.

Mr. Aman Anavkar, Chief Growth Officer, Fabtech Technologies Limited, said: “Entering CIS country through a project of this technical complexity is an important milestone for Fabtech. The mandate is not simply to supply infrastructure, but to engineer a manufacturing environment around the process, the local climate and the customer’s long-term operating requirements. Bringing design, utilities, cleanroom systems, HVAC, electrical integration and validation thinking under one execution framework is central to the value we bring to this project.”

As pharmaceutical manufacturing capacity expands across emerging markets, Fabtech Technologies remains focused on leveraging its engineering expertise, international presence and execution capabilities to participate in the next phase of global healthcare infrastructure development.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Fabtech Technologies Limited

Fabtech Technologies Limited belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.

Fabtech trades in the lower quarter of its 52-week range. The PEG of 0.64 signals undervaluation relative to growth. It is a potential re-rating candidate. Revenue grows at 28.3% and profits at 20.8% CAGR. Both numbers are exceptional. The stock sits at 10% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 28.3% and profits at 20.8% CAGR — a genuinely strong business. Nevertheless, the stock drops 7.1% in three months. The market sells the stock, not the story. Watch whether that changes at the next earnings. Check Fundamentals of Fabtech Technologies Limited.

Fabtech Technologies Limited (FABTECH) has successfully completed a 14,000 sqm turnkey facility for Himalaya Wellness Company in Dubai, UAE. This milestone highlights the company’s engineering prowess and project execution discipline. The facility, delivered in less than a year, supports pharmaceutical and cosmetic manufacturing operations with different cleanroom requirements.

Project Execution and Delivery

The project was managed by Fabtech’s Step Down Subsidiary, FTS Cleanrooms Systems LLC, UAE. The integrated approach to the build allowed the design, installation, and validation to be managed under a single delivery structure. This ensured the project was completed within the planned timeframe of less than a year, showcasing the efficiency of the project team.

Significance of the Facility

The completed facility forms part of Himalaya’s manufacturing operations in Dubai, providing cleanroom infrastructure for the production of pharmaceutical and cosmetic products. Mr. Aman Anavkar, Chief Growth Officer, Fabtech Technologies Limited, emphasized the importance of this project in validating the company’s engineering capabilities and project execution discipline.

As pharmaceutical manufacturing capacity expands across emerging markets, Fabtech Technologies remains focused on leveraging its engineering expertise and international presence to participate in the next phase of global healthcare infrastructure development.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Fabtech Technologies Limited

Fabtech Technologies Limited belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.

Fabtech posts a 0.1% three-month gain, but softens in the last few weeks. The PEG of 0.64 signals undervaluation relative to growth. It is a potential re-rating candidate. Revenue grows at 28.3% and profits at 20.8% CAGR. Both numbers are exceptional. The stock gives back 0.1% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 28.3% and profits at 20.8%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Fabtech Technologies Limited.

Fabtech Technologies Limited (FABTECH) has secured an AED 9.92 million turnkey project for Aroma King, a flavour manufacturing company in the UAE, through its wholly owned subsidiary FTS Cleanrooms Systems LLC. The project, scheduled for fast-track completion within six months, will deliver the facility’s critical internal infrastructure, including modular controlled environments, cold rooms, specialised flooring, high- and low-side HVAC systems, and internal electrical works under an integrated, single-source execution model.

Expanding Critical Infrastructure Platform

Flavour manufacturing requires precise control of temperature, humidity, hygiene, and production environments to ensure consistency and product quality. This project leverages Fabtech Group’s engineering expertise in controlled environments and mission-critical infrastructure to create a modern, efficient, and future-ready manufacturing facility. The win also demonstrates the strategic role of FTS Cleanrooms Systems LLC as Fabtech’s regional execution platform, expanding the Group’s capabilities into high-specification food, flavour, and ingredient manufacturing while strengthening its presence in the UAE.

Advancing Global Vision

This project advances Fabtech’s broader vision of becoming a global critical infrastructure platform — extending its expertise in precision environments, HVAC, utilities, and integrated engineering into industries where manufacturing conditions are mission-critical. Fabtech Technologies Limited — engineering critical infrastructure for the industries of tomorrow.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Fabtech Technologies Limited

Fabtech Technologies Limited belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.

Fabtech trades in the lower quarter of its 52-week range. The PEG of 0.65 signals undervaluation relative to growth. It is a potential re-rating candidate. Revenue grows at 28.3% and profits at 20.8% CAGR. Both numbers are exceptional. The stock sits at 12% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 28.3% and profits at 20.8% CAGR — a genuinely strong business. Nevertheless, the stock drops 3.6% in three months. The market sells the stock, not the story. Watch whether that changes at the next earnings. Check Fundamentals of Fabtech Technologies Limited.